PharVision Advisers’s Veritex Holdings VBTX Stock Holding History

PharVision Advisers’s Portfolio VBTX Stock Details VBTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-20,340	Closed	-$508K	–	438
2025 Q1	$508K	Buy	+20,340	New	+$524K	0.7%	15

Other funds holding VBTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

PharVision Advisers's VBTX Position: Q2 2025 in Review

PharVision Advisers sold out of Veritex Holdings (VBTX) in Q2 2025, closing a stake of 20,340 shares — an estimated $508K sold.

PharVision Advisers first reported a position in VBTX in Q1 2025 and held it in 1 quarter. The position peaked at $508K in Q1 2025. 246 funds tracked by Wall St. Rank hold VBTX as of Q2 2025.

PharVision Advisers reported no remaining Veritex Holdings position as of Q2 2025 after selling out during the quarter.
PharVision Advisers sold 20,340 Veritex Holdings shares in Q2 2025, an estimated $508K.
PharVision Advisers first reported a position in Veritex Holdings in Q1 2025 and held it in 1 quarter.
PharVision Advisers's Veritex Holdings position peaked at $508K in Q1 2025.
246 funds tracked by Wall St. Rank held Veritex Holdings as of Q2 2025.

Based on PharVision Advisers's 13F filing for Q2 2025, filed 13 Aug 2025.